Demenz bei Parkinson-Syndromen: Lewy-Körper-Demenz, idiopathisches und andere Parkinson-Syndrome, Normaldruckhydrozephalus

A. O. Ceballos-Baumann

doi:10.1055/s-0038-1626818

Nervenheilkunde, Table of Contents

Nervenheilkunde 2006; 25(12): 1046-1056
DOI: 10.1055/s-0038-1626818

Original- und Übersichtsarbeiten - Original and Review Articles

Schattauer GmbH

Demenz bei Parkinson-Syndromen: Lewy-Körper-Demenz, idiopathisches und andere Parkinson-Syndrome, Normaldruckhydrozephalus

2. Teil – TherapieTherapy of dementia in parkinsonismLewy bodies dementia, Parkinson’s disease, and other forms of parkinsonism including normal pressure hydrocephalus

Authors

A. O. Ceballos-Baumann

¹Neurologisches Krankenhaus München

Abstract

Zusammenfassung

Das Erkennen von Demenz bei Parkinson-Syndromen bzw. von einem Parkinson-Syndrom bei einer dementiellen Entwicklung ist hilfreich, um durch die Wahl geeigneter und Meidung ungeeigneter Pharmaka folgende häufige iatrogene Probleme zu reduzieren: 1. Delire und Psychosen durch Antiparkinsonika und 2. motorische und kognitive Verschlechterung durch typische und auch atypische Neuroleptika. Bei neu aufgetretener dementieller Symptomatik bei Parkinson-Syndrom müssen zunächst auslösende Ursachen ausgeschlossen werden: Dehydrierung, Medikamente, Harnwegsinfekte und Pneumonien, metabolische Störungen, Herzinsuffizienz und Anämien. Abrupte Entzüge von Medikamenten wie Amantadin und Anticholinergika sind zu vermeiden. Studienergebnisse sprechen für eine wichtige Rolle von Cholinesterasehemmer bei Lewy-Körper-Demenz (LKD) und idiopathischem Parkinson-Syndrom (IPS) mit Demenz. Clozapin und Quetiapin (nicht zugelassen) sind als delirogene Pharmaka ungeeignet bei Demenz und sollten der typischen dopaminergen Psychose bei IPS vorbehalten bleiben.

Summary

The diagnosis of dementia in the context of parkinsonism or respectively of parkinsonism in dementia is the first step to minimize the following common iatrogenic problems: 1. delirium and psychosis caused by antiparkinsonian drugs and 2. motor and cognitive worsening caused by typical and atypical neuroleptics. An emerging dementia in parkinsonism asks for the exclusion of precipitating causes such as dehydration, drugs, urinary infections, pneumonia and metabolic causes before any other measures are taken. Sudden withdrawals of amantadine and anticholinergics should be avoided. Trials suggest an important role of cholinesterase-inhibitors in the treatment of Lewy body dementia and Parkinson’s disease with dementia. Clozapin and Quetiapine (off label) are potentially delirogenic compounds and if possible should be avoided in dementia and reserved for the classical dopaminergic psychosis.

Schlüsselwörter

Parkinson-Syndrom - Demenz - atypische Neuroleptika - Cholinesterasehemmer - Dopaminergika

Keywords

Parkinson’s disease - parkinsonism and dementia - atypical neuroleptics - cholinesterase inhibitors - dopamine agonists

Full Text

References

Literatur
1 Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. Jama 2002; 287: 1653-61.
2 Aarsland D, Hutchinson M, Larsen JP. Cognitive, psychiatric and motor response to galantamine in Parkinson’s disease with dementia. Int J Geriatr Psychiatry 2003; 18: 937-41.
3 Aarsland D, Laake K, Larsen JP, Janvin C. Donepezil for cognitive impairment in Parkinson’s disease: a randomised controlled study. J Neurol Neurosurg Psychiatry 2002; 72: 708-12.
4 Adams RD, Fisher CM, Hakim S, Ojemann RG, Sweet WH. Symptomatic Occult Hydrocephalus with “Normal” Cerebrospinal-Fluid Pressure.A Treatable Syndrome. N Engl J Med 1965; 273: 117-26.
5 Ancoli-Israel S, Martin JL, Gehrman P, Shochat T, Corey-Bloom J, Marler M. et al. Effect of light on agitation in institutionalized patients with severe Alzheimer disease. Am J Geriatr Psychiatry 2003; 11: 194-203.
6 Baezner H, Oster M, Henning O, Cohen S, Hennerici MG. Amantadine increases gait steadiness in frontal gait disorder due to subcortical vascular encephalopathy: a double-blind randomized placebocontrolled trial based on quantitative gait analysis. Cerebrovasc Dis 2001; 11: 235-44.
7 Ballard CG, O’Brien JT, Reichelt K, Perry EK. Aromatherapy as a safe and effective treatment for the management of agitation in severe dementia: the results of a double-blind, placebo-controlled trial with Melissa. J Clin Psychiatry 2002; 63 (07) 553-8.
8 Barclay CL, Lang AE. Dystonia in progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 1997; 62: 352-6.
9 Bergman J, Lerner V. Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson’s disease. Clin Neuropharmacol 2002; 25: 107-10.
10 Bohnen NI, Kaufer DI, Ivanco LS, Lopresti B, Koeppe RA, Davis JG. et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol 2003; 60: 1745-8.
11 Bonelli SB, Ransmayr G, Steffelbauer M, Lukas T, Lampl C, Deibl M. L-dopa responsiveness in dementia with Lewy bodies, Parkinson disease with and without dementia. Neurology 2004; 63: 376-8.
12 Brandstadter D, Oertel WH. Treatment of drug-induced psychosis with quetiapine and clozapine in Parkinson’s disease. Neurology 2002; 58: 160-1.
13 Burke WJ, Pfeiffer RF, McComb RD. Neuroleptic sensitivity to clozapine in dementia with Lewy bodies. J Neuropsychiatry Clin Neurosci 1998; 10 (02) 227-9.
14 Ceballos-Baumann AO. Demenz bei ParkinsonSyndromen: Klinik und Therapie. Nervenheilkunde 2003; 22: 287-94.
15 Ceballos-Baumann AO. Idiopathisches Parkinson-Syndrom: Grundlagen, Medikamente, Therapieeinleitung. In: Ceballos-Baumann AO, Conrad B. (eds). Bewegungsstörungen in der Neurologie. 2 überarbeitete Auflage. Stuttgart, New York: Thieme; 2005: 33-70.
16 Ceballos-Baumann AO, Boecker H, Bartenstein P, von Falkenhayn I, Riescher H, Conrad B. et al. A PET study of subthalamic nucleus stimulation in Parkinson´s disease: Enhanced movement related activity of motor association cortex and decreased motor cortex resting activity. Arch Neurol. 1999
17 Ceballos-Baumann AO, Kurz A. Parkinson-Syndrome mit Demenz. In: Ceballos-Baumann AO, Conrad B. (eds). Bewegungsstörungen in der Neurologie. Stuttgart, NewYork: Thieme; 2005: 106-27.
18 Ceballos-Baumann AO, Petri S, Toelle T, Heckmann M, Conrad B. Neues in der Botulinum-Toxin Therapie: von der Dystonie bis zur Migränepropylaxe. Nervenheilkunde. 2000
19 Dautzenberg PL, Wouters CJ, Oudejans I, Samson MM. Rivastigmine in prevention of delirium in a 65 years old man with Parkinson’s disease. Int J Geriatr Psychiatry 2003; 18: 555-6.
20 De Deyn PP, Rabheru K, Rasmussen A, Bocksberger JP, Dautzenberg PL, Eriksson S. et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia [see comments]. Neurology 1999; 53: 946-55.
21 Defazio G, De Mari M, De Salvia R, Lamberti P, Giorelli M, Livrea P. “Apraxia of eyelid opening” induced by levodopa therapy and apomorphine in atypical parkinsonism (possible progressive supranuclear palsy): a case report. Clin Neuropharmacol 1999; 22: 292-4.
22 Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP. et al. Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med 2004; 351 (24) 2509-18.
23 Engel PA. Treatment of progressive supranuclear palsy with amitriptyline: therapeutic and toxic effects. J Am Geriatr Soc 1996; 44: 1072-4.
24 Esmonde T, Cooke S. Shunting for normal pressure hydrocephalus (NPH). Cochrane Database Syst Rev 2002; CD003157.
25 Factor SA, Molho ES, Brown DL. Acute delirium after withdrawal of amantadine in Parkinson’s disease. Neurology 1998; 50: 1456-8.
26 Fernandez HH, Friedman JH, Jacques C, Rosenfeld M. Quetiapine for the treatment of drug-induced psychosis in Parkinson’s disease. Mov Disord 1999; 14: 484-7.
27 Fernandez HH, Trieschmann ME, Burke MA, Friedman JH. Quetiapine for psychosis in Parkinson’s disease versus dementia with Lewy bodies. J Clin Psychiatry 2002; 63: 513-5.
28 Fernandez HH, Trieschmann ME, Burke MA, Jacques C, Friedman JH. Long-term outcome of quetiapine use for psychosis among Parkinsonian patients. Mov Disord 2003; 18: 510-4.
29 Forstl H, Burns A, Luthert P, Cairns N, Levy R. The Lewy-body variant of Alzheimer’s disease. Clinical and pathological findings. Br J Psychiatry 1993; 162: 385-92.
30 Frank AM, Ceballos-Baumann A. Tiefe Hirnstimulation bei idiopathischem Parkinson-Syndrom und essentiellem Tremor: Grundlagen, Indikationsstellung, peri- und intra--operatives Vorgehen, Perspektiven. Nervenheilkunde 2005; 24: 884-902.
31 Friedman JH, Factor SA. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson’s disease. Mov Disord 2000; 15: 201-11.
32 Geroldi C, Frisoni GB, Bianchetti A, Trabucchi M. Drug treatment in Lewy body dementia. Dement Geriatr Cogn Disord 1997; 08 (03) 188-97.
33 Giladi N, Shabtai H, Gurevich T, Benbunan B, Anca M, Korczyn AD. Rivastigmine (Exelon) for dementia in patients with Parkinson’s disease. Acta Neurol Scand 2003; 108: 368-73.
34 Goetz CG, Blasucci LM, Leurgans S, Pappert EJ. Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology 2000; 55: 789-94.
35 Grace J, Daniel S, Stevens T, Shankar KK, Walker Z, Byrne EJ. et al. Long-Term use of rivastigmine in patients with dementia with Lewy bodies: an open-label trial. Int Psychogeriatr 2001; 13: 199-205.
36 Graham JM, Sussman JD, Ford KS, Sagar HJ. Olanzapine in the treatment of hallucinosis in idiopathic Parkinson’s disease: a cautionary note. J Neurol Neurosurg Psychiatry 1998; 65: 774-7.
37 Group TPS. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson’s disease. [see comments]. N Engl J Med 1999; 340: 757-63.
38 Hansen LA, DeTeresa R, Davies P, Terry RD. Neocortical morphometry, lesion counts, and choline acetyltransferase levels in the age spectrum of Alzheimer’s disease. Neurology 1988; 38: 48-54.
39 Haupt M, Karger A, Baumgartner D, Kuminoti D, Janner M, Schneider F. [Improvement of agitation and anxiety in dementia patients after psychoeducative training of their caregivers]. Fortschr Neurol Psychiatr 2000; 68: 216-23.
40 Herrmann N. Valproic acid treatment of agitation in dementia. Can J Psychiatry 1998; 43: 69-72.
41 Hutchinson M, Fazzini E. Cholinesterase inhibition in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1996; 61: 324-5.
42 Jobges M, Heuschkel G, Pretzel C, Illhardt C, Renner C, Hummelsheim H. Repetitive training of compensatory steps: a therapeutic approach for postural instability in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2004; 75: 1682-7.
43 Kannus P, Parkkari J, Niemi S, Pasanen M, Palvanen M, Jarvinen M. et al. Prevention of hip fracture in elderly people with use of a hip protector. N Engl J Med 2000; 343: 1506-13.
44 Kaufer DI. A case study in the treatment of dementia with Lewy bodies. Acta Psychiatr Scand. 2004 110. 73-5 discussion 75–6.
45 Kompoliti K, Goetz CG, Litvan I, Jellinger K, Verny M. Pharmacological therapy in progressive supranuclear palsy. Arch Neurol 1998; 55: 1099-102.
46 Lemke MR. Effect of carbamazepine on agitation in Alzheimer’s inpatients refractory to neuroleptics. J Clin Psychiatry 1995; 56: 354-7.
47 Litvan I. Diagnosis and management of progressive supranuclear palsy. Semin Neurol 2001; 21: 41-8.
48 Lonergan ET, Cameron M, Luxenberg J. Valproic acid for agitation in dementia. Cochrane Database Syst Rev 2004; CD003945.
49 Maidment I, Fox C, Boustani M. Cholinesterase inhibitors for Parkinson’s disease dementia. Cochrane Database Syst Rev 2006; CD004747.
50 Manfredi PL, Breuer B, Wallenstein S, Stegmann M, Bottomley G, Libow L. Opioid treatment for agitation in patients with advanced dementia. Int J Geriatr Psychiatry 2003; 18: 700-5.
51 Manson AJ, Schrag A, Lees AJ. Low-dose olanzapine for levodopa induced dyskinesias. Neurology 2000; 55: 795-9.
52 Mark MH, Sage JI, Walters AS, Duvoisin RC, Miller DC. Binswanger’s disease presenting as levodopa-responsive parkinsonism: clinicopathologic study of three cases [see comments]. Mov Disord 1995; 10: 450-4.
53 Matsumoto T, Kawanishi C, Isojima D, Iseki E, Kishida I, Kosaka K. Neuroleptic malignant syndrome induced by donepezil. Int J Neuropsychopharmacol 2004; 07: 101-3.
54 McGaffigan S, Bliwise DL. The treatment of sundowning. The treatment of sundowning. Drugs Aging 1997; 10: 10-7.
55 McKeith I, Del Ser T, Spano P, Emre M, Wesnes K, Anand R. et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000; 356: 2031-6.
56 McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H. et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005; 65: 1863-72.
57 McManus DQ, Arvanitis LA, Kowalcyk BB. Quetiapine, a novel antipsychotic: experience in elderly patients with psychotic disorders. Seroquel Trial 48 Study Group. J Clin Psychiatry 1999; 60: 292-8.
58 Meehan KM, Wang H, David SR, Nisivoccia JR, Jones B, Beasley Jr CM. et al. Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology 2002; 26: 494-504.
59 Menendez-Gonzalez M, Calatayud MT, Blazquez-Menes B. Exacerbation of Lewy bodies dementia due to memantine. J Alzheimers Dis 2005; 08: 289-91.
60 Olin JT, Fox LS, Pawluczyk S, Taggart NA, Schneider LS. A pilot randomized trial of carbamazepine for behavioral symptoms in treatmentresistant outpatients with Alzheimer disease. Am J Geriatr Psychiatry 2001; 09: 400-5.
61 Ondo WG, Levy JK, Vuong KD, Hunter C, Jankovic J. Olanzapine treatment for dopaminergic-induced hallucinations. Mov Disord 2002; 17: 1031-5.
62 Onofrj M, Thomas A. Severe worsening of parkinsonism in Lewy body dementia due to donepezil. Neurology 2003; 61: 1452.
63 Onofrj M, Thomas A, Iacono D, Luciano AL, Di Iorio A. The effects of a cholinesterase inhibitor are prominent in patients with fluctuating cognition: a part3 study of the main mechanism of cholinesterase inhibitors in dementia. Clin Neuropharmacol 2003; 26: 239-51.
64 Parkinson-Study-Group Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Jama 2000; 284: 1931-8.
65 Poewe W, Wolters E, Emre M, Onofrj M, Hsu C, Tekin S. et al. Long-term benefits of rivastigmine in dementia associated with Parkinson’s disease: An active treatment extension study. Mov Disord. 2005
66 Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa 056 Study Group. N Engl J Med 2000; 342: 1484-91.
67 Reading PJ, Luce AK, McKeith IG. Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Mov Disord 2001; 16: 1171-4.
68 Reddy S, Factor SA, Molho ES, Feustel PJ. The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia. Mov Disord 2002; 17: 676-81.
69 Ridha BH, Josephs KA, Rossor MN. Delusions and hallucinations in dementia with Lewy bodies: worsening with memantine. Neurology 2005; 65: 481-2.
70 Rojas-Fernandez CH. Successful use of donepezil for the treatment of dementia with Lewy bodies. Ann Pharmacother 2001; 35: 202-5.
71 Sabbagh MN, Hake AM, Ahmed S, Farlow MR. The use of memantine in dementia with Lewy bodies. J Alzheimers Dis 2005; 07: 285-9.
72 Schroeder U, Kuehler A, Lange KW, Haslinger B, Tronnier VM, Krause M. et al. Subthalamic nucleus stimulation affects a frontotemporal network: a PET study. Ann Neurol 2003; 54: 445-50.
73 Shea C, MacKnight C, Rockwood K. Donepezil for treatment of dementia with Lewy bodies: a case series of nine patients. Int Psychogeriatr 1998; 10: 229-38.
74 Sterzer P, Meintzschel F, Rosler A, Lanfermann H, Steinmetz H, Sitzer M. Pravastatin improves cerebral vasomotor reactivity in patients with subcortical small-vessel disease. Stroke 2001; 32: 2817-20.
75 Tariot PN, Erb R, Podgorski CA, Cox C, Patel S, Jakimovich L. et al. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry 1998; 155: 54-61.
76 Tiraboschi P, Hansen LA, Alford M, Merdes A, Masliah E, Thal LJ. et al. Early and widespread cholinergic losses differentiate dementia with Lewy bodies from Alzheimer disease. Arch Gen Psychiatry 2002; 59: 946-51.
77 Weiner WJ, Minagar A, Shulman LM. Pramipexole in progressive supranuclear palsy. Neurology 1999; 52: 873-4.
78 Wild R, Pettit T, Burns A. Cholinesterase inhibitors for dementia with Lewy bodies. Cochrane Database Syst Rev 2003; D003672.
79 Winikates J, Jankovic J. Clinical correlates of vascular parkinsonism. Arch Neurol 1999; 56: 98-102.
80 Zijlmans JC, Katzenschlager R, Daniel SE, Lees AJ. The L-dopa response in vascular parkinsonism. J Neurol Neurosurg Psychiatry 2004; 75: 545-7.
81 EMEA/CHMP/31718/2006. http://www.emea. eu.int/pdfs/human/opinion/3171806en.pdf.